Terumo (OTCMKTS:TRUMY) Stock Price Down 4.8% - Should You Sell?

Key Points

• Terumo Corp.'s stock price dropped 4.8% to $17.81, with trading volume down significantly to 3,925 shares compared to an average of 158,856 shares.
• The company's most recent quarterly earnings showed an EPS of $0.20, exceeding estimates, but revenue came in lower than expected at $1.76 billion against a $1.80 billion forecast.
• Terumo has a market capitalization of $26.32 billion and operates in multiple segments including Cardiac and Vascular products, indicating a diverse range within the healthcare sector.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) fell 4.8% on Monday . The stock traded as low as $17.81 and last traded at $17.81. 3,925 shares were traded during trading, a decline of 98% from the average session volume of 158,856 shares. The stock had previously closed at $18.71.

Terumo Stock Down 5.0%

The company has a market cap of $26.32 billion, a P/E ratio of 31.19 and a beta of 0.80. The business's 50 day moving average price is $17.62 and its 200-day moving average price is $18.22. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.00 and a quick ratio of 1.78.

Terumo (OTCMKTS:TRUMY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. Terumo had a return on equity of 9.30% and a net margin of 12.09%.The business had revenue of $1.76 billion for the quarter, compared to analyst estimates of $1.80 billion.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.